
    
      APR003 is a small molecule TLR7 agonist that concentrates in the GI, and liver with limited
      systemic exposure. It is designed to increase the therapeutic window of a TLR7 agonist by
      minimizing the side-effects associated with generalized systemic immune activation and
      inflammation.
    
  